-
IRAK Related Products (43)
Related Products (43)
-
IRAK4-IN-28
0 ImagesCat. No.: HY-155132CAS No.: 2952532-92-0
-
ND-2158
0 ImagesCat. No.: HY-120041CAS No.: 1388896-07-8
-
FLT3/IRAK4-IN-1
0 ImagesCat. No.: HY-176735FLT3/IRAK4-IN-1 is a selective FLT3/IRAK4 inhibitor with the remarkable activity towards FLT3-WT (IC50 = 1.95 nM), FLT3-D835Y (IC50 = 3.22 nM) and IRAK4 (IC50 = 53.72 nM). LT3/IRAK4-IN-1 has relatively low toxicity to normal bone marrow cells, can effectively promote cell apoptosis, and has the potential to overcome drug resistance. FLT3/IRAK4-IN-1 can be used for research on acute myeloid leukemia (AML).
-
IRAK4 aa104-460 Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70731The IRAK4 protein is a serine/threonine protein kinase that is critical for initiating the innate immune response through the Toll-like receptor (TLR) and IL-1R signaling pathways. After TLR is activated, it rapidly forms the Myddosome with IRAK2. IRAK4 aa104-460 Recombinant Human Active Protein Kinase is a recombinant IRAK4 aa104-460 protein that can be used to study IRAK4 aa104-460-related functions.
-
IRAK4-IN-25
0 ImagesCat. No.: HY-155518CAS No.: 2952533-47-8IRAK4-IN-25 (compound 38) is an orally acitve and potent IRAK4 inhibitor (IC50=7.3 nM), with low clearance (Cl=12 mL/min/kg). IRAK4-IN-25 inhibits production of pro-inflammatory cytokines, and shows in vitro safety and ADME profiles. IRAK4-IN-25 can be used for research in inflammatory and autoimmune disorders.
-
PC-046
0 ImagesCat. No.: HY-120561CAS No.: 1202401-59-9PC-046 is a multi-target inhibitor for tyrosine receptor kinase B (TrkB), IRAK-4 and Pim-1, with IC50 of 13.4 μM, 15.4 μM and 19.1 μM, respectively. PC-046 exhibits cytotoxicity against pancreatic cancer cell BxPC3 with IC50 of 7.5-130 nM. PC-046 induces apoptosis and arrests cell cycle at G2/M phase in BxPC3. PC-046 exhibits antitumor efficacy and exhibits good pharmacokinetic characteristics in mice.
-
IRAK4-IN-26
0 ImagesCat. No.: HY-155519CAS No.: 2952533-49-0IRAK4-IN-26 (Compound 21) is a IRAK4 inhibitor (IC50: 6.2 nM). IRAK4-IN-26 displays an oral bioavailability of 21%. IRAK4-IN-26 can be used for research of inflammatory and autoimmune disorders.
-
2,4′-Dihydroxybenzophenone (Standard)
0 ImagesCat. No.: HY-W014223RCAS No.: 131-56-6Synonyms: Ultraviolet absorber UV-0 (Standard)2,4′-Dihydroxybenzophenone (Standard) is the analytical standard of 2,4′-Dihydroxybenzophenone. This product is intended for research and analytical applications. 2,4′-Dihydroxybenzophenone (Ultraviolet absorber UV-0) occupies the hydrophobic pocket of MD2 and blocks the dimerization of TLR4. 2,4′-Dihydroxybenzophenone inhibits the LPS induced mtROS production, and LPS induced inflammatory response by downregulating pro-inflammatory mediators and decreasing the expression of MyD88, p-IRAK4, and NF-κB. 2,4′-Dihydroxybenzophenone is also a UV absorber.
-
JH-X-119-01 hydrochloride (Standard)
0 ImagesCat. No.: HY-103017RCAS No.: 2591344-30-6JH-X-119-01 hydrochloride (Standard) is the analytical standard of JH-X-119-01 hydrochloride (HY-103017). This product is intended for research and analytical applications. JH-X-119-01 hydrochloride is a potent and selective interleukin-1 receptor-associated kinases 1 (IRAK1) inhibitor. JH-X-119-01 hydrochloride ameliorates LPS-induced sepsis in mice.
-
Emavusertib phosphate
0 ImagesCat. No.: HY-135317FCAS No.: 2376399-38-9Synonyms: CA-4948 phosphateEmavusertib phosphate (CA-4948 phosphate) is the phosphate salt form of Emavusertib (HY-135317). Emavusertib phosphate is an orally active inhibitor for IRAK4 (IC50=57 nM) and FLT3. Emavusertib phosphate inhibits NF-κB and MyD88 signaling pathways, reduces the generation of pro-inflammatory cytokines like IL-6 and IL-10, thereby exhibiting anti-inflammatory and anti-proliferative activities against cancer cells, leading to cell apoptosis. Emavusertib phosphate exhibits antitumor activity in mouse model.
-
AZ1495 (Standard)
0 ImagesCat. No.: HY-111101RCAS No.: 2196204-23-4AZ1495 (Standard) is the analytical standard of AZ1495 (HY-111101). This product is intended for research and analytical applications. AZ1495, a weak base, is a potent orally active interleuKin-1 receptor associated Kinase 4 (IRAK4) inhibitor. AZ1495 has a favorable physicochemical and Kinase selectivity for IRAK4 and IRAK1 with IC50 values of 0.005 μM and 0.023 μM, respectively. AZ1495 has IRAK4 inhibition with a Kd value of 0.0007 μM. AZ1495 can be used for the research of diffuse large B-cell lymphoma (DLBCL).
-
IRAK4-IN-1 (Standard)
0 ImagesCat. No.: HY-101922RCAS No.: 1820787-94-7IRAK4-IN-1 (Standard) is the analytical standard of IRAK4-IN-1 (HY-101922). This product is intended for research and analytical applications. IRAK4-IN-1 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor with an IC50 of 7 nM.
-
Emavusertib maleate
0 ImagesCat. No.: HY-135317ECAS No.: 2376399-39-0Synonyms: CA-4948 maleateEmavusertib maleate (CA-4948 maleate) is the maleate salt form of Emavusertib (HY-135317). Emavusertib maleate is an orally active inhibitor for IRAK4 (IC50=57 nM) and FLT3. Emavusertib maleate inhibits NF-κB and MyD88 signaling pathways, reduces the generation of pro-inflammatory cytokines like IL-6 and IL-10, thereby exhibiting anti-inflammatory and anti-proliferative activities against cancer cells, leading to cell apoptosis. Emavusertib maleate exhibits antitumor activity in mouse model.
-
ND-2110
0 ImagesCat. No.: HY-117622CAS No.: 1388894-17-4ND-2110 is a selective IRAK4 inhibitor (Ki: 7.5 nM). ND-2110 binds to the ATP pocket of IRAK4. ND-2110 targets the subset of activated B cell-like (ABC) subtype of diffuse large B cell lymphoma (DLBCL) cell lines with MYD88 L265P mutations,. ND-2110 inhibits LPS-induced TNF production, alleviates collagen-induced arthritis, and blocks gout formation in mouse models.
-
Emavusertib tosylate
0 ImagesCat. No.: HY-135317CCAS No.: 2376399-41-4Synonyms: CA-4948 tosylateEmavusertib tosylate (CA-4948 tosylate) is the tosylate salt form of Emavusertib (HY-135317). Emavusertib tosylate is an orally active inhibitor for IRAK4 (IC50=57 nM) and FLT3. Emavusertib tosylate inhibits NF-κB and MyD88 signaling pathways, reduces the generation of pro-inflammatory cytokines like IL-6 and IL-10, thereby exhibiting anti-inflammatory and anti-proliferative activities against cancer cells, leading to cell apoptosis. Emavusertib tosylate exhibits antitumor activity in mouse model.
